Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial details
- Registry ID
- NCT07703436
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseNCT07703436 | NUVB | Phase 2 | Recruiting | 2030-09Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |